Readycell participated in the annual meeting of the StretchBio Project, which was held at the Danmarks Tekniske Universitet (DTU) in Copenhagen.
An investigation led by the researcher Nicoló Milani was published in the prestigious analytical journal Lab on a Chip. The CacoGoblet kit was employed to investigate the permeability and the metabolism of the compound in a gut-liver-organ-on-a-chip (OoC).
Caco-2 cells assay is a reference assayto evaluate intestinal permeability in drug discovery stages, optimizing novel compounds screening.
Our ReadyCell sales representative Carla Sapienza will travel next August 29th, 30th and 31st to Boston to attend the Brain Barriers Summit, an event that aims to join industry experts through a discursive forum and evaluate how neuropharmaceuticals can be targeted.
The publication, entitled Daily Intraperitoneal Administration of RGZ Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia, was aimed at testing the efficacy of three types of Thiazolidenoides (TZN) in preterm rabbits with bronchopulmonary dysplasia.
OATP1B1 and OATP1B3 are two influx transporters of the SLCO gene family that are primarily expressed in the sinusoidal membrane of hepatocytes.
Last month, the ICH launched a draft on Drug Interaction Studies regulatory. The guideline includes the regulations of the European, American and Japanese medical agencies and covers both in vitro and clinical studies.
Understanding the role of these transporters in the clearance of new molecular entities (NME) is normally performed in-vitro at the early stages of drug development.
We are happy to have with us Csenge Barabás, Nóra Kovács, Joseph Zolnerciksand and Dávid Bajkó to discuss a range of topics and to visit our facilities.
ReadyCell will support academic research through its sponsorship at the IX BiotechHealth Symposium, which will be held on 28 June in Porto.